Elevated Hemoglobin or Hematocrit
Pt with true polycythemia with an increased red blood cell (RBC) mass.
Pt with a relative polycythemia and a normal RBC mass as a result of dehydration or another state producing a low plasma volume.
Polycythemia in which the RBC mass is high enough to impair blood flow.
Commonly Encountered Situations
Polycythemia vera, also known as primary polycythemia, is not secondary to any disorder.
Polycythemia from an underlying disorder (secondary polycythemia) is much more common than primary polycythemia.
Suggested Additional Lab Testing
Serum erythropoietin level is low in primary polycythemia, unlike secondary polycythemia, so the erythropoietin (EPO) level can be useful in separating primary and secondary polycythemia.
Strict criteria are required for the diagnosis of polycythemia vera: (A1 plus A2 plus any other A) or (A1 plus A2 plus any 2B) criteria:
Increased RBC mass by hemoglobin, hematocrit, or RBC number (A1)
Erythrocytosis is not secondary to another cause (A2)
Clonal cytogenetic abnormality other than the Philadelphia chromosome (A4)
Endogenous erythroid colony formation in vitro (A5)
Platelet count greater than 400,000/µL (B1)
WBC count greater than 12,000/µL (B2)
Panmyelosis on bone marrow biopsy (B3)
Low serum EPO (B4)
Bone marrow biopsy may be useful to determine if polycythemia vera is in a hypercellular phase with greater than 60% cellularity or in a hypocellular bone marrow with markedly increased reticulin fibers.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States